Applications of Aurintricarboxylic Acid in Industrial Manufacturing

Aurintricarboxylic acid supports precise downstream processes in specialized industrial sectors, offering unique benefits as an inhibitor, chelating agent, and diagnostic reagent. Our manufacturing expertise ensures strict material consistency for high-stakes applications. Below are verified segments where this raw material is integral for performance, quality, and compliance.

1. Molecular Biology Research Reagents

Within life sciences, laboratories rely on aurintricarboxylic acid to selectively inhibit ribonuclease and endonuclease activity during RNA and DNA extraction, protecting nucleic acids from enzymatic degradation during complex molecular workflows. Researchers integrate this agent at critical lysis or extraction steps to stabilize high-purity samples for sensitive downstream analysis. Each formulation demands precise ratio adjustments depending on sample type and nucleic acid yield, a process monitored to align with international laboratory reagent requirements for accuracy and safety.

Industry compliance standards

• ISO 9001:2015 for quality management
• ISO 13485:2016 for in vitro diagnostic reagent production
• REACH regulation (EC 1907/2006) for chemical substances
• OECD Principles of Good Laboratory Practice

Typical usage ratio

• 0.05–0.5 mM in lysis or extraction buffers; adjusted by sample total RNA/DNA yield and tolerance for downstream enzymatic sensitivity

Downstream process integration

• Direct addition to the cell or tissue lysis solution during RNA/DNA isolation procedures, before centrifugal separation or precipitation steps

Final product types

• Ready-to-use RNA and DNA isolation kits
• Bulk molecular reagent sets for biotechnology labs
• Research-grade extraction buffers
• Diagnostic reagent kits for in vitro molecular tests

2. Enzyme Inhibition in Pharmaceutical Process Development

Pharmaceutical manufacturers utilize this material to inhibit nucleases or regulate enzyme-driven reactions within small-scale synthesis and pilot production. Integration occurs during in-process controls for therapeutic nucleic acid and oligonucleotide production, where maintaining intact substrates is decisive for downstream purity, yield consistency, and compliance with international good manufacturing standards. Technical staff tailor ratios based on substrate load and sensitivity for each batch protocol.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients
• European Pharmacopoeia 10.0 (reagent grade)
• United States Pharmacopeia (USP) for analytical reagent use
• 21 CFR Part 211 (FDA cGMP for finished pharmaceuticals)

Typical usage ratio

• Variable, 0.02–0.2 mM depending on nucleic acid substrate concentration and enzyme activity profile; laboratory validation dictates ratio on a batch-by-batch basis

Downstream process integration

• Incorporation into reaction vessels during oligonucleotide synthesis, followed by removal during purification, or addition to in-process controls during nucleic acid drug formulation

Final product types

• Pharmaceutical-grade oligonucleotide APIs
• Therapeutic siRNA and antisense drug intermediates
• Nucleic acid–based reference standards
• Quality control benchmarks for bioanalytical laboratories

3. Diagnostic Assay Stabilization

IVD (in vitro diagnostics) manufacturers apply this raw material in specialized buffer systems to secure nucleic acid targets against degradation, especially during sample storage, handling, and high-sensitivity diagnostic testing. Integration follows precise formulation protocols for real-time PCR and nucleic acid test kits where integrity against environmental interference is paramount. Material use aligns with rigorous traceability and lot-release controls anchored to medical device quality frameworks.

Industry compliance standards

• ISO 13485:2016 for medical device and IVD manufacturing
• EN 13612:2002 (performance evaluation for IVDs)
• US FDA 21 CFR 820 (Quality System Regulation for IVDs)
• IVDR (EU) 2017/746 (In Vitro Diagnostic Regulation)

Typical usage ratio

• 0.01–0.10 mM in final diagnostic reagent or buffer preparations; precise ratio determined by sample nucleic acid stability requirements and shelf-life claims

Downstream process integration

• Formulation into sample preservation buffers before kit filling and lyophilization; verification of stabilizing effect during validation and product lot release

Final product types

• PCR/RT-PCR assay kits for hospital and laboratory diagnostics
• Nucleic acid sample collection and transport kits
• Stabilized specimen preservation tubes
• Pre-filled liquid biopsy collection devices

4. Metal Ion Scavenging in Bioprocessing

Bioprocess engineers leverage the chelating properties of this material to bind metal ions and prevent unwanted oxidative reactions in sensitive protein and nucleic acid purification systems. It enters the process during column preparation or buffer formulation steps, helping reduce trace metal-induced degradation across production runs. Its inclusion supports process control objectives and batch reproducibility critical for biotechnological product quality and regulatory compliance.

Industry compliance standards

• EU GMP Annex 2 for biological active substances
• ICH Q9 (Quality Risk Management)
• USP <1043> Ancillary Materials for Cell, Gene, and Tissue-Engineered Products
• ISO 14644 (Cleanroom standards for biomanufacturing)

Typical usage ratio

• 0.02–0.12 mM in buffer preparations; ratio adjusted based on process metal ion load and downstream protein/nucleic acid compatibility tolerance

Downstream process integration

• Addition to buffer solutions during preparation prior to chromatographic protein or nucleic acid purification; sometimes added pre-sterile filtration stage to ensure absence of transition metals

Final product types

• Biopharmaceutical-grade protein purification kits
• Chromatography media buffers for large-scale production
• Reagent-grade cell culture buffers
• Bioprocessing cleaning-in-place (CIP) solutions